OneOncology to build OpenEvidence's AI search into its cancer doctors' software

What the two companies announced

OpenEvidence, an AI-powered search and decision-support tool for doctors, and OneOncology, a physician-led network of independent specialty practices, announced a partnership on August 6, 2026. As openevidence.com reported in its own press release, OpenEvidence will be built into certain clinical applications that OneOncology's practices already use.

The stated purpose is to let physicians look up evidence, find references and do research without leaving their normal working screens. The idea is to cut out the step of switching to a separate website or app in the middle of a busy clinic day.

What 'inside the workflow' means

Doctors can already use OpenEvidence on its own. The change here is placement. Instead of opening a separate tool, a physician at a OneOncology partner practice would reach it from within the software they already use for patient care. The release calls the moment of a patient visit the "point of care", meaning the time when a clinician needs an answer right away.

The companies also describe a second phase, without giving dates. Over time they expect to connect OpenEvidence to two OneOncology resources. One is its structured genomic data, meaning genetic test results about tumors stored in an organized, searchable form. The other is its clinical trial matching systems, which help identify studies a patient might qualify for.

If that happens, a doctor could see published evidence, a patient's genetic findings and nearby trial options in one place. The release describes this as evidence, precision oncology insights and research opportunities lining up together. Precision oncology means choosing treatment based on the specific genetic features of a person's cancer.

Why community cancer care is the target

The release points out that more than 50 percent of cancer patients in the United States are treated at community oncology practices. These are local, often independent clinics rather than large university hospitals. OneOncology says its partner practices care for 1.5 million patients, and describes a network of roughly 2,300+ providers across 20 states.

The workload is heavy. According to the release, community physicians manage hundreds of approved therapies across dozens of tumor types. They also follow treatment rules built on biomarkers, which are measurable signs such as a particular gene change that help decide which drug fits. Those rules shift each time a new therapy is approved. Community practices also increasingly offer clinical trials that used to be mostly available at academic centers.

OneOncology's chief medical officer, Davey Daniel, said the network's doctors read constantly and that the tool should help them reach current research more efficiently. A practice leader at Coastal Cancer Center in Myrtle Beach, SC, said having it inside her workflow would make it easier to get information when she needs it.

What to keep in mind

This is a company announcement, and the usage claims in it come from the companies. OpenEvidence says more than half of US hematology/oncology physicians already use it, and says independent studies show more American physicians use it than all other AI platforms combined. The release does not name those studies. The tool is described as free for verified US clinicians, and that matches the lack of any price or fee in the announcement.

The release also leaves out a lot. It does not say which applications will get the tool, when it will go live, how many practices will have it, or how the genomic and trial features will work. It offers no results showing better decisions or outcomes. Nobody has yet shown that easier access translates into better care.

The OpenEvidence chief medical officer, Travis Zack, said oncology is where the information problem in medicine is sharpest, because the literature moves fast and decisions are increasingly individualized. That is a fair description of the challenge. Whether a search tool meets it is something practices and patients will learn from use, not from a press release.